PureTech Health plc (PRTC) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2024
Loading P/E history...
PRTC Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, PureTech Health plc (PRTC) trades at a price-to-earnings ratio of -0.4x, with a stock price of $16.97 and trailing twelve-month earnings per share of $-23.20.
The current P/E is 102% below its 5-year average of 17.9x. Over the past five years, PRTC's P/E has ranged from a low of 5.9x to a high of 35.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, PRTC trades at a 102% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, PRTC trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PRTC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PRTC P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | - | +68% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $536B | 38.4 | - | -58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PRTC Historical P/E Data (2020–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $18.46 | $0.80 | 23.1x | +29% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $37.00 | $1.05 | 35.2x | +97% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $49.00 | $6.60 | 7.4x | -59% |
| FY2020 Q4 | $54.00 | $9.20 | 5.9x | -67% |
Average P/E for displayed period: 17.9x
See PRTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRTC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRTC — Frequently Asked Questions
Quick answers to the most common questions about buying PRTC stock.
Is PRTC stock overvalued or undervalued?
PRTC trades at -0.4x P/E, below its 5-year average of 17.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does PRTC's valuation compare to peers?
PureTech Health plc P/E of -0.4x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is PRTC's PEG ratio?
PRTC PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2024.